Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results

AI Summary

Biogen (BIIB) shares dropped 6% following the announcement of positive data from an Alzheimer's drug trial. The trial outcomes, while favorable, did not meet market expectations for immediate approval or broader commercial viability. This decline reflects investor skepticism regarding the drug's potential impact on revenue growth and market positioning. The market will be watching closely for further developments that could influence Biogen's stock performance.